Insilico Medicine Pharma.AI
Save to shortlistLast reviewed Nov 11, 2026 against the sources listed on this page · How we review
At a glance
Insilico Medicine's Pharma.AI platform (PandaOmics for target discovery and Chemistry42 for generative chemistry) uses deep learning and generative models to identify disease targets and design…
- FDA:
- Not on record
- Epic:
- Not on record
- Named users:
- Not on record
- Published study:
- Yes, linked below
Description
Insilico Medicine's Pharma.AI platform (PandaOmics for target discovery and Chemistry42 for generative chemistry) uses deep learning and generative models to identify disease targets and design novel small molecules. Its AI-discovered lead candidate INS018_055, a TNIK inhibitor for idiopathic pulmonary fibrosis, has advanced into clinical trials, one of the first fully generative-AI-originated drugs to do so.
Quick answers
Answered only from the sourced records on this page. Questions we can't answer from the record are left out. How we review
- Is there published research on Insilico Medicine Pharma.AI?
- Yes, this listing links a study (prospective / randomized study). Check whether the patients and setting in the study look like yours.Some authors of this study work for or have financial ties to the maker.Read the study
Security & contracting
The maker has not reported these details yet. Ask the vendor directly during evaluation.
- Workflow stage
- Not reported
- Integrations
- Not reported
- Data inputs
- Not reported
- Deployment
- Not reported
- Signs a BAA
- Not reported
- SOC 2 report
- Not reported
- HITRUST
- Not reported
- Evidence type
- Prospective / randomized study
- Study authors
- Include people who work for or have financial ties to the maker
Readiness details are self-reported by the maker and are not checked by Clinical Intelligence Foundry. Evidence type describes the kind of study or document the listing links to; it is not a rating or endorsement. Confirm compliance documents with the vendor before purchase.
Who's using this
Organizations named in public announcements or by the developer. Inclusion is not an endorsement.
No public deployments found yet (checked Oct 2026). Using this tool? The maker can claim the listing to add customers.
Get weekly updates for Drug Discovery
Up to 5 new items a week: new tools, FDA decisions and studies. Newest first, never ranked. Confirm by email, unsubscribe any time.
Sources
This listing links to primary sources. Follow the links below to check details directly with the developer, regulator or publication.
Website Research PaperSome authors of this study work for or have financial ties to the maker.
Developer
Insilico Medicine
Insilico Medicine, Inc.
Evaluating this tool?
Get a printable packet for your committee: what the public record shows, the gaps to raise with the vendor, and the questions for this kind of tool.
Prepare evaluation packetChecklist for your role: Admin · Physician · IT · Compliance
Compare similar tools →